Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

1
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
1
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

3
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
3
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

2
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
2
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. オブストラクティブ・ハイパートロフィック・カルディオミオパシーにおけるセプト・リダクション療法後の長期的結果: Share レジストリからの洞察

オブストラクティブ・ハイパートロフィック・カルディオミオパシーにおけるセプト・リダクション療法後の長期的結果: SHARE レジストリからの洞察

Niccolò Maurizi1,2, Panagiotis Antiochos2, Anjali Owens3

  • 1Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy (N.M., C.F., I.O.).

Circulation
|October 2, 2024

関連する実験動画

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.4K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.2K
Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.0K

PubMed で要約を見る

まとめ
この要約は機械生成です。

セプト縮小療法 (SRT) は,閉塞性多動性心筋病 (HCM) の症状を効果的に緩和する. しかし,高齢と女性の性別は,治療後の心不全のリスクを高め,長期のモニタリングが必要になります.

キーワード:
心筋病 縮症心不全左心室の縮ミエクトミー

関連する実験動画

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.4K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.2K
Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.0K

科学分野:

  • 心臓病科
  • 心臓外科
  • 遺伝学

背景:

  • 阻害性多動性心筋病 (HCM) は患者の生活の質に重大な影響を及ぼします.
  • セプトの縮小療法 (SRT) は症状の緩和をもたらすが,長期的な結果は検査が必要である.

研究 の 目的:

  • 長期の病気の進行を評価し,阻害性HCMのSRT後の有害な結果の予測要因を特定する.

主な方法:

  • 13の国際HCMセンター (SHARE登録) の1832人の患者のデータを分析した.
  • 心不全 (HF),心室不律,HCMに関連する死亡を含む複合的なアウトカムについて,患者さんを追跡した.
  • コックスの比例リスクモデルは,有害事象の予測要因を特定した.

主要な成果:

  • SRTの30日死亡率は0. 4%でした.
  • 平均6. 8年の追跡期間を経て,13%が複合性HFのアウトカム,5%が心房不律のアウトカムを経験した.
  • SRTの年齢と女性の性別は,HFのリスクの増加と関連しており,21%でde novo心房細動が起こりました.

結論:

  • SRTは,経験豊富なセンターで,流出管の阻害を短期的かつ長期的に効果的に軽減します.
  • 10年後の無事故生存率は83%で,心室不律はまれでした.
  • 高齢,女性,小児のSRTは手術後のHFリスクが高くなります.